Alto Neuroscience Inc
(ANRO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -61,431 | -36,305 | -27,710 | -9,187 |
| Depreciation Amortization | 502 | 373 | 342 | 145 |
| Accounts receivable | N/A | N/A | N/A | -1,285 |
| Accounts payable and accrued liabilities | 516 | -632 | 1,006 | 458 |
| Other Working Capital | 4,060 | -698 | 4,579 | -572 |
| Other Operating Activity | 8,929 | 3,814 | 1,389 | 1,179 |
| Operating Cash Flow | $-47,424 | $-33,448 | $-20,394 | $-9,262 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -2,075 | -470 | -732 | -680 |
| Investing Cash Flow | $-2,075 | $-470 | $-732 | $-680 |
| Cash Flows From Financing Activities | ||||
| Debt Issued | 1,250 | N/A | 9,825 | N/A |
| Common Stock Issued | 137,766 | 181 | 43 | 7 |
| Other Financing Activity | -3,325 | 67,949 | 33,921 | 31,681 |
| Financing Cash Flow | $135,691 | $68,130 | $43,789 | $31,688 |
| Exchange Rate Effect | -11 | -8 | -24 | -50 |
| Beginning Cash Position | 82,548 | 48,344 | 25,705 | 4,009 |
| End Cash Position | 168,729 | 82,548 | 48,344 | 25,705 |
| Net Cash Flow | $86,181 | $34,204 | $22,639 | $21,696 |
| Free Cash Flow | ||||
| Operating Cash Flow | -47,424 | -33,448 | -20,394 | -9,262 |
| Capital Expenditure | -2,075 | -470 | -732 | -680 |
| Free Cash Flow | -49,499 | -33,918 | -21,126 | -9,942 |